Cargando…
COVID-19 in patients with cancer: Risks and precautions
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS),...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840397/ https://www.ncbi.nlm.nih.gov/pubmed/33546958 http://dx.doi.org/10.1016/j.ajem.2021.01.067 |
_version_ | 1783643567792586752 |
---|---|
author | Razavi, AzadehSadat Hamblin, Michael R. Rezaei, Nima |
author_facet | Razavi, AzadehSadat Hamblin, Michael R. Rezaei, Nima |
author_sort | Razavi, AzadehSadat |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS), which often leads to death, especially in those with underlying diseases. It has been reported that those who suffer from cancer (especially lung cancer and hematological malignancies) are at higher risk of serious complications and death from COVID-19. Some cancer treatments such as CAR T cell therapy can produce a cytokine storm, which is also a hallmark of severe COVID-19. Therefore, patients receiving CAR T cells are at higher risk if they become infected with COVID-19, and could be treated with anti-cytokine approaches. |
format | Online Article Text |
id | pubmed-7840397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78403972021-01-28 COVID-19 in patients with cancer: Risks and precautions Razavi, AzadehSadat Hamblin, Michael R. Rezaei, Nima Am J Emerg Med Article Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the coronavirus family, which causes coronavirus disease 2019 (COVID-19). The phenotype of the disease varies from asymptomatic, to a mild phenotype, through to the severe form of acute respiratory distress syndrome (ARDS), which often leads to death, especially in those with underlying diseases. It has been reported that those who suffer from cancer (especially lung cancer and hematological malignancies) are at higher risk of serious complications and death from COVID-19. Some cancer treatments such as CAR T cell therapy can produce a cytokine storm, which is also a hallmark of severe COVID-19. Therefore, patients receiving CAR T cells are at higher risk if they become infected with COVID-19, and could be treated with anti-cytokine approaches. Elsevier Inc. 2021-10 2021-01-28 /pmc/articles/PMC7840397/ /pubmed/33546958 http://dx.doi.org/10.1016/j.ajem.2021.01.067 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Razavi, AzadehSadat Hamblin, Michael R. Rezaei, Nima COVID-19 in patients with cancer: Risks and precautions |
title | COVID-19 in patients with cancer: Risks and precautions |
title_full | COVID-19 in patients with cancer: Risks and precautions |
title_fullStr | COVID-19 in patients with cancer: Risks and precautions |
title_full_unstemmed | COVID-19 in patients with cancer: Risks and precautions |
title_short | COVID-19 in patients with cancer: Risks and precautions |
title_sort | covid-19 in patients with cancer: risks and precautions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840397/ https://www.ncbi.nlm.nih.gov/pubmed/33546958 http://dx.doi.org/10.1016/j.ajem.2021.01.067 |
work_keys_str_mv | AT razaviazadehsadat covid19inpatientswithcancerrisksandprecautions AT hamblinmichaelr covid19inpatientswithcancerrisksandprecautions AT rezaeinima covid19inpatientswithcancerrisksandprecautions |